These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28407075)

  • 21. Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
    Brown K; Patterson-Browning B; Liu C; Patel M; Stewart L; Nettles RE
    Rev Recent Clin Trials; 2017; 12(3):174-181. PubMed ID: 28403798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
    Gutierrez-Valencia A; Benmarzouk-Hidalgo OJ; Llaves S; Fernandez-Magdaleno T; Espinosa N; Viciana P; Lopez-Cortes LF
    J Antimicrob Chemother; 2017 Mar; 72(3):816-819. PubMed ID: 27999051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
    Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
    Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint.
    Boyd SD; Sampson MR; Viswanathan P; Struble KA; Arya V; Sherwat AI
    AIDS; 2019 May; 33(6):1089-1093. PubMed ID: 30946163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
    Barceló C; Gaspar F; Aouri M; Panchaud A; Rotger M; Guidi M; Cavassini M; Buclin T; Decosterd LA; Csajka C;
    J Antimicrob Chemother; 2016 Jul; 71(7):1933-42. PubMed ID: 27029846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
    Momper JD; Wang J; Stek A; Shapiro DE; Powis KM; Paul ME; Badell ML; Browning R; Chakhtoura N; Denson K; Rungruengthanakit K; George K; Capparelli EV; Mirochnick M; Best BM;
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):303-309. PubMed ID: 34732682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
    Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
    J Antimicrob Chemother; 2017 Jul; 72(7):2143. PubMed ID: 28482097
    [No Abstract]   [Full Text] [Related]  

  • 29. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.
    Krishna R; East L; Larson P; Valiathan C; Deschamps K; Luk JA; Bethel-Brown C; Manthos H; Brejda J; Gartner M
    Biopharm Drug Dispos; 2016 Dec; 37(9):533-541. PubMed ID: 27696440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration.
    Gervasoni C; Resnati C; Formenti T; Fossati A; Minisci D; Meraviglia P; Cattaneo D
    Antivir Ther; 2018; 23(5):467-469. PubMed ID: 29300165
    [No Abstract]   [Full Text] [Related]  

  • 31. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
    Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
    HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
    Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
    J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
    Gervasoni C; Riva A; Cozzi V; Capetti A; Rizzardini G; Clementi E; Cattaneo D
    J Antimicrob Chemother; 2017 Jun; 72(6):1842-1844. PubMed ID: 28333266
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
    Acosta EP; Kendall MA; Gerber JG; Alston-Smith B; Koletar SL; Zolopa AR; Agarwala S; Child M; Bertz R; Hosey L; Haas DW
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3104-10. PubMed ID: 17576825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
    Sherman EM; Worley MV; Unger NR; Gauthier TP; Schafer JJ
    Clin Ther; 2015 Sep; 37(9):1876-93. PubMed ID: 26319088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
    Curran A; Pérez-Valero I; Moltó J
    AIDS Rev; 2015; 17(2):114-20. PubMed ID: 26035169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers.
    Kakuda TN; Van De Casteele T; Petrovic R; Neujens M; Salih H; Opsomer M; Hoetelmans RM
    Antivir Ther; 2014; 19(6):597-606. PubMed ID: 24964392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.